NEW YORK (GenomeWeb) – Natera said today that it has struck a distribution deal with Thermo Fisher Scientific's One Lamda to co-distribute its cell-free DNA-based kidney transplant rejection test in the US.
Parisa Khosropour, president of transplant diagnostics at Thermo Fisher Scientific, said in a statement that Natera's cfDNA test "complements [its] existing transplant offerings and enables us to provide a more advanced portfolio for monitoring kidney rejection."
Natera CEO Steve Chapman said that the firm would still have its own direct sales team when it launches its test this year, but would also be able to leverage One Lambda's commercial infrastructure.
The company published a validation study of its kidney transplant rejection assay in the Journal of Clinical Medicine last December, retrospectively analyzing 300 plasma samples from 193 patients. Last month, Natera said that it had submitted a dossier to the Centers for Medicare and Medicaid Services for reimbursement and anticipated that its test would be priced at a similar rate to CareDx's cfDNA assay for kidney transplant rejection of $2,800.